Protein subunit vaccines: Promising frontiers against COVID-19

J Control Release. 2024 Feb:366:761-782. doi: 10.1016/j.jconrel.2024.01.017. Epub 2024 Jan 20.

Abstract

The emergence of COVID-19 has posed an unprecedented global health crisis, challenging the healthcare systems worldwide. Amidst the rapid development of several vaccine formulations, protein subunit vaccines have emerged as a promising approach. This article provides an in-depth evaluation of the role of protein subunit vaccines in the management of COVID-19. Leveraging viral protein fragments, particularly the spike protein from SARS-CoV-2, these vaccines elicit a targeted immune response without the risk of inducing disease. Notably, the robust safety profile of protein subunit vaccines makes them a compelling candidate in the management of COVID-19. Various innovative approaches, including reverse vaccinology, virus like particles, and recombinant modifications are incorporated to develop protein subunit vaccines. In addition, the utilization of advanced manufacturing techniques facilitates large-scale production, ensuring widespread distribution. Despite these advancements, challenges persist, such as the requirement for cold-chain storage and the necessity for booster doses. This article evaluates the formulation and applications of protein subunit vaccines, providing a comprehensive overview of their clinical development and approvals in the context of COVID-19. By addressing the current status and challenges, this review aims to contribute to the ongoing discourse on optimizing protein subunit vaccines for effective pandemic control.

Keywords: COVID-19; Protein-based vaccines; SARS-CoV-2; Subunit vaccines.

Publication types

  • Review

MeSH terms

  • COVID-19* / prevention & control
  • Cryopreservation
  • Humans
  • Pandemics
  • Protein Subunit Vaccines
  • SARS-CoV-2

Substances

  • Protein Subunit Vaccines